Novartis
Novartis eyes genomics route for flu vaccines
October 11, 2010Manufacturing and Production, Research and Development Novartis, Synthetic Genomics Vaccines, genomics
Novartis will make use of a technology developed by Synthetic Genomics Vaccines, a new company set up by genomics pioneer …
Novartis drops two drug candidates, takes $600 million hit
October 6, 2010Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis
Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …
Novartis sells bladder treatment rights to Warner Chilcott
September 24, 2010Sales and Marketing Enablex, Novartis, Warner Chilcott
Novartis is to sell the US rights to market its overactive bladder treatment Enablex to Warner Chilcott. Novartis will receive …
Gilenya approved as new frontline MS treatment
September 22, 2010Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya
Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …
Novartis hails longer-lasting COPD drug
September 20, 2010Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler
A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …
Swiss approval for Novartis’ Tasigna
August 31, 2010Sales and Marketing Novartis, Tasigna, Tekamlo
Novartis’ Tasigna has received its first European approval as a first-line treatment after Swiss authorities green-lighted the blood cancer drug …
Alcon acquisition makes Novartis eyecare leader
August 26, 2010Sales and Marketing Novartis, ophthalmology
Novartis has finalised its takeover of Alcon that will make it the world’s number one company in ophthalmology. Alcon is …
Pharma provides aid for Pakistan
August 24, 2010Sales and Marketing GSK, NGO, Novartis, Pakistan, disaster, pharma, relief
The pharma industry is providing donations to help those affected by the mass flooding across Pakistan. As many as 20 …
Novartis and Quark sign gene silencing deal
August 19, 2010Research and Development Novartis, Quark, SiRNA, rnai
Novartis has joined the race to develop a ‘gene silencing’ treatment by signing a new deal with siRNA specialist Quark …
NICE decides Xolair is not value for money
August 12, 2010Sales and Marketing NICE, Novartis, Xolair
NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …
Two $1 billion dollar acquisition deals go through
August 11, 2010Sales and Marketing Alcon, M&A, MA, Novartis, Ratiopharm, Teva
Two major acquisition deals mounted by Teva and Novartis are in their final stages as they move to complete potentially …
Digital Pharma: Novartis rapped for Facebook sharing
August 10, 2010Medical Communications Digital Pharma blog, Facebook, Novartis, Tasigna
Novartis has had its knuckles rapped by the FDA over the company’s use of social media sharing tools. At issue …
Digital Pharma: Novartis game takes aim at ticks
July 30, 2010Medical Communications Digital Pharma blog, Novartis, digital patients, disease awareness campaigns, encephalitis
Novartis has launched a new online game to raise awareness of the risks posed by ticks and how to avoid …
New products spur Novartis growth
July 15, 2010Sales and Marketing Novartis, Tasigna
Novartis has posted strong results for the second quarter of the year. The Swiss pharma company posted an 11% rise …
NICE poised to reject Novartis’ Afinitor
July 8, 2010Sales and Marketing Afinitor, NICE, Novartis
Novartis’ kidney cancer drug Afinitor does not offer enough benefit to patients to justify its cost, according to draft guidance …
